A comparison of four self-controlled study designs in an analysis of COVID-19 vaccines and myocarditis using five European databases
Copyright © 2024 The Authors. Published by Elsevier India Pvt Ltd. All rights reserved..
INTRODUCTION: The aim of this study was to assess the possible extent of bias due to violation of a core assumption (event-dependent exposures) when using self-controlled designs to analyse the association between COVID-19 vaccines and myocarditis.
METHODS: We used data from five European databases (Spain: BIFAP, FISABIO VID, and SIDIAP; Italy: ARS-Tuscany; England: CPRD Aurum) converted to the ConcePTION Common Data Model. Individuals who experienced both myocarditis and were vaccinated against COVID-19 between 1 September 2020 and the end of data availability in each country were included. We compared a self-controlled risk interval study (SCRI) using a pre-vaccination control window, an SCRI using a post-vaccination control window, a standard SCCS and an extension of the SCCS designed to handle violations of the assumption of event-dependent exposures.
RESULTS: We included 1,757 cases of myocarditis. For analyses of the first dose of the Pfizer vaccine, to which all databases contributed information, we found results consistent with a null effect in both of the SCRI and extended SCCS, but some indication of a harmful effect in a standard SCCS. For the second dose, we found evidence of a harmful association for all study designs, with relatively similar effect sizes (SCRI pre = 1.99, 1.40 - 2.82; SCRI post 2.13, 95 %CI - 1.43, 3.18; standard SCCS 1.79, 95 %CI 1.31 - 2.44, extended SCCS 1.52, 95 %CI = 1.08 - 2.15). Adjustment for calendar time did not change these conclusions. Findings using all designs were also consistent with a harmful effect following a second dose of the Moderna vaccine.
CONCLUSIONS: In the context of the known association between COVID-19 vaccines and myocarditis, we have demonstrated that two forms of SCRI and two forms of SCCS led to largely comparable results, possibly because of limited violation of the assumption of event-dependent exposures.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Vaccine - 42(2024), 12 vom: 30. Apr., Seite 3039-3048 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Schultze, Anna [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
(MeSH): Vaccines |
|---|
| Anmerkungen: |
Date Completed 22.04.2024 Date Revised 22.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.vaccine.2024.03.043 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370699254 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370699254 | ||
| 003 | DE-627 | ||
| 005 | 20240422232359.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240406s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.vaccine.2024.03.043 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1383.xml |
| 035 | |a (DE-627)NLM370699254 | ||
| 035 | |a (NLM)38580517 | ||
| 035 | |a (PII)S0264-410X(24)00330-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Schultze, Anna |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A comparison of four self-controlled study designs in an analysis of COVID-19 vaccines and myocarditis using five European databases |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.04.2024 | ||
| 500 | |a Date Revised 22.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The Authors. Published by Elsevier India Pvt Ltd. All rights reserved. | ||
| 520 | |a INTRODUCTION: The aim of this study was to assess the possible extent of bias due to violation of a core assumption (event-dependent exposures) when using self-controlled designs to analyse the association between COVID-19 vaccines and myocarditis | ||
| 520 | |a METHODS: We used data from five European databases (Spain: BIFAP, FISABIO VID, and SIDIAP; Italy: ARS-Tuscany; England: CPRD Aurum) converted to the ConcePTION Common Data Model. Individuals who experienced both myocarditis and were vaccinated against COVID-19 between 1 September 2020 and the end of data availability in each country were included. We compared a self-controlled risk interval study (SCRI) using a pre-vaccination control window, an SCRI using a post-vaccination control window, a standard SCCS and an extension of the SCCS designed to handle violations of the assumption of event-dependent exposures | ||
| 520 | |a RESULTS: We included 1,757 cases of myocarditis. For analyses of the first dose of the Pfizer vaccine, to which all databases contributed information, we found results consistent with a null effect in both of the SCRI and extended SCCS, but some indication of a harmful effect in a standard SCCS. For the second dose, we found evidence of a harmful association for all study designs, with relatively similar effect sizes (SCRI pre = 1.99, 1.40 - 2.82; SCRI post 2.13, 95 %CI - 1.43, 3.18; standard SCCS 1.79, 95 %CI 1.31 - 2.44, extended SCCS 1.52, 95 %CI = 1.08 - 2.15). Adjustment for calendar time did not change these conclusions. Findings using all designs were also consistent with a harmful effect following a second dose of the Moderna vaccine | ||
| 520 | |a CONCLUSIONS: In the context of the known association between COVID-19 vaccines and myocarditis, we have demonstrated that two forms of SCRI and two forms of SCCS led to largely comparable results, possibly because of limited violation of the assumption of event-dependent exposures | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a (MeSH): Vaccines | |
| 650 | 4 | |a Electronic Health Records | |
| 650 | 4 | |a Meta-analysis | |
| 650 | 4 | |a Myocarditis | |
| 650 | 4 | |a Pharmacoepidemiology | |
| 650 | 4 | |a Self-controlled Case Series | |
| 650 | 4 | |a Self-controlled Risk Interval | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Vaccines |2 NLM | |
| 700 | 1 | |a Martin, Ivonne |e verfasserin |4 aut | |
| 700 | 1 | |a Messina, Davide |e verfasserin |4 aut | |
| 700 | 1 | |a Bots, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Belitser, Svetlana |e verfasserin |4 aut | |
| 700 | 1 | |a José Carreras-Martínez, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Correcher-Martinez, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Urchueguía-Fornes, Arantxa |e verfasserin |4 aut | |
| 700 | 1 | |a Martín-Pérez, Mar |e verfasserin |4 aut | |
| 700 | 1 | |a García-Poza, Patricia |e verfasserin |4 aut | |
| 700 | 1 | |a Villalobos, Felipe |e verfasserin |4 aut | |
| 700 | 1 | |a Pallejà-Millán, Meritxell |e verfasserin |4 aut | |
| 700 | 1 | |a Alberto Bissacco, Carlo |e verfasserin |4 aut | |
| 700 | 1 | |a Segundo, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Souverein, Patrick |e verfasserin |4 aut | |
| 700 | 1 | |a Riefolo, Fabio |e verfasserin |4 aut | |
| 700 | 1 | |a Durán, Carlos E |e verfasserin |4 aut | |
| 700 | 1 | |a Gini, Rosa |e verfasserin |4 aut | |
| 700 | 1 | |a Sturkenboom, Miriam |e verfasserin |4 aut | |
| 700 | 1 | |a Klungel, Olaf |e verfasserin |4 aut | |
| 700 | 1 | |a Douglas, Ian |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Vaccine |d 1985 |g 42(2024), 12 vom: 30. Apr., Seite 3039-3048 |w (DE-627)NLM012600105 |x 1873-2518 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2024 |g number:12 |g day:30 |g month:04 |g pages:3039-3048 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.vaccine.2024.03.043 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2024 |e 12 |b 30 |c 04 |h 3039-3048 | ||